However, previous findings in the literature support the novel concept that a monoclonal antibody can extend in vivo pharmacokinetics of an aptamer without reducing the tumor-targeting and anticancer effects of the aptamer [68], even though the reported immunoconjugate was not bispecific as it was made up of the cotinine-conjugated anti-VEGF pegaptanib aptamer and an anti-cotinine antibody. The gene discussed is VEGFA; the disease is neoplasm.